When the Data Don't Fit the Dogma: Five Trials That Changed How We Think

The AUA 2026 plenary includes a session called “When the Data Don’t Fit the Dogma,” led by Freddie Hamdy with Seth Lerner, Brian Rini, and Ian Thompson. Four people who ran the trials that made urologists sit up straight.

This isn’t a conference summary. It’s the five trials I keep coming back to when I realise something I was taught as settled fact was actually an assumption waiting to be tested.

1. ProtecT: Not All Prostate Cancer Needs Treating Now

Men with localised prostate cancer randomised to active surveillance, radical prostatectomy, or radiotherapy. At 15 years, prostate cancer-specific mortality was low in all three groups (2.7% overall, no significant difference between arms). Metastases were more common with active surveillance, but survival wasn’t.

I was taught “definitive treatment saves lives.” The honest version is: for many men with localised disease, survival is excellent whichever path you choose, and the real conversation is about treatment toxicity versus progression risk. Not one answer. A conversation.

Active surveillance isn’t doing nothing. It’s a structured strategy to avoid overtreatment without missing the window for cure.

2. PIVOT: Surgery Isn’t Automatically Better

Radical prostatectomy versus observation in localised prostate cancer. Surgery did not significantly reduce all-cause or prostate cancer mortality in the overall population through long follow-up. Some higher-risk subgroups may have benefited, but the headline landed clearly: operating on every PSA-detected cancer doesn’t automatically save lives.

The question isn’t “can we operate?” It’s “is this cancer biologically significant enough, and will this patient live long enough, for radical treatment to change what actually matters?“

3. CARMENA: The Kidney Doesn’t Always Come Out First

Metastatic RCC. For years, cytoreductive nephrectomy was reflex: kidney out, then systemic therapy. CARMENA showed sunitinib alone was non-inferior to nephrectomy-then-sunitinib in patients who needed systemic treatment.

This didn’t end cytoreductive nephrectomy. It ended the assumption that it must always come first. Patients with poor-risk disease or high metastatic burden may actually be harmed by delaying systemic therapy for major surgery. The lesson is about selection, not abolition.

One caveat worth knowing: CARMENA was a targeted therapy era trial. Modern RCC uses immunotherapy combinations, so the principle holds but the application needs current MDT thinking.

4. SWOG 8710: Bladder Cancer Is Not Just a Surgical Disease

Neoadjuvant MVAC before cystectomy versus cystectomy alone for muscle-invasive bladder cancer. Median survival 77 months with chemo first versus 46 months with surgery alone.

“Remove the bladder, job done” was the old thinking. SWOG 8710 reframed MIBC as a systemic-risk disease even when imaging looks clean. Which means the MDT question isn’t just “is this patient fit for cystectomy?” - it’s also “are they cisplatin-fit, and has neoadjuvant chemo been properly discussed?“

5. POUT: Upper Tract Cancer Needs More Than Nephroureterectomy

Upper tract urothelial carcinoma is awkward. Remove the kidney and ureter, renal function drops, and suddenly adjuvant cisplatin-based chemotherapy becomes impossible. POUT showed adjuvant gemcitabine-platinum after nephroureterectomy significantly improved disease-free survival: 71% versus 46% at three years (HR 0.45).

“Remove and observe” was the default. POUT says high-risk UTUC needs early oncology input, and that conversation should happen before the nephroureterectomy. If adjuvant chemo is likely, post-op renal function matters, which means MDT sequencing is the whole game.